Glenmark Initiates Phase IIb Human Trials Globally For Its Novel Molecule 'Revamilast'
Glenmark Pharmaceuticals announced that its Novel Chemical Entity "Revamilast" (GRC 4039) has initiated Phase IIb human dose range finding trials globally...
If you have orthopedic information that you would like to share with the Orthogate Community, please register/login and submit your news, event, job, article, case or workshop from the Submit Content menu under the My Account area. Learn more!